<?xml version="1.0"?><?xml-stylesheet type="text/xsl" href="drug-table.xslt"?><drug name = "ranitidine liq ORAL">
<dose><value>150</value>
<value>300</value>
</dose>
<route><value>PO</value>
</route>
<strength><value>15 mg/mL</value>
</strength>
<frequency><value>DAILY</value>
<value>BID</value>
<value>HS</value>
<value>ONCE</value>
</frequency>
<instruction><value>Administer pre-operatively.</value>
<value>DAY 1 of 21. If oral ranitidine has not been taken by patient as instructed, administer 60 minutes pre-PACLitaxel. May be administered by IV route.</value>
<value>DAY 1 of 21. May be administered by IV route.</value>
<value>DAY 1 of 7. If oral ranitidine has not been taken by patient as instructed, administer 60 minutes pre-PACLitaxel. May be administered by IV route.</value>
<value>DAY 1 of 7. May be administered by IV route.</value>
</instruction>
<volume></volume>
<units><value>mg</value>
</units>
<Population><value>Adjuvant PACLitaxel/CARBOplatin. Non-Small Cell Lung Cancer</value>
<value>PACLitaxel / CARBOplatin. Advanced / Metastatic Non-Small Cell Lung Cancer</value>
<value>PACLitaxel/CARBOplatin (Weekly) and concurrent RT. Non-Small Cell Lung Cancer.</value>
</Population>
<IndicationPRN></IndicationPRN>
<AdditionalNotes></AdditionalNotes>
<BackgroundInformation><value>alcohol free formulation</value>
</BackgroundInformation>
<PRNInformation><value>YES</value>
</PRNInformation>
<AHSFormularyStatus><value>Formulary.</value>
</AHSFormularyStatus>
<AHFSName><value>Antiulcer Agents and Acid Suppressants, Histamine H2-Antagonists</value>
</AHFSName>
<HighAlert></HighAlert>
</drug>